Skip to main content
SpringerLink
Log in

Immunobiology of melanoma

  • Chapter
Clinical Management of Melanoma

Part of the book series: Developments in Oncology ((DION,volume 5))

Abstract

In discussing the immunobiology of a particular form of human cancer, in this case, melanoma, one makes the tacit assumption that the tumor cells express certain moieties which are not expressed on the normal adult cellular counterpart. Secondly, one also assumes that the host is, to some extent, able to recognize these tumor associated antigens (TAA) as foreign and to respond against them with either a cellular or humoral reaction, or with both. Early studies performed in inbred rodent model systems successfully demonstrated that both virally induced and carcinogen-induced tumors did express such TAA and that, under appropriate conditions, these TAA did provoke a vigorous antitumor immune response [146]. Clinically speaking, the human melanoma TAA of greatest interest are those located on the cell membrane as these would be accessible on the viable tumor cell to the host antitumor immune response. As will be discussed in this chapter, in addition to cell membrane TAA, melanoma cells may also express cytoplasmic and nucleolar TAA. These, however, appear to be of much less importance clinically because of their inaccessibility as targets for immune destruction of the cell.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Avis P and Lewis MG: Tumor-associated fetal antigens in human tumors. J Natl Cancer Inst 51:1063–1066, 1973.

    PubMed  CAS  Google Scholar 

  2. Balda BR, Hehlmann R, Cho JR and Spiegelman S: Oncornavirus-like particles in human skin cancers. Proc Natl Acad Sci 72:3697–3700, 1975.

    PubMed  CAS  Google Scholar 

  3. Baldwin RW, Embleton MJ, Jones JSP and Langman MJS: Cell mediated and humoral immune reactions to human tumors. Int J Cancer 12:73–83, 1973.

    PubMed  CAS  Google Scholar 

  4. Bauer HW, Deutschmann KEM, Peter HH and Bohn H: Pregnancy associated α-glycoprotein in malignant melanoma. Eur J Cancer 15:123–126, 1979.

    PubMed  CAS  Google Scholar 

  5. Bernengo MG, Capella G, DeMatteis A, Tovo PA and Zina G : The in vitro effects of a calf thymus extract on the peripheral blood lymphocytes of sixty-six melanoma patients. Clin Exp Immunol 36:279–284, 1979.

    PubMed  CAS  Google Scholar 

  6. Birkmayer GD, Hammer C, Eberhard HD and Brendel W: A tumor specific antigen associated with reverse transcriptase. Behring Inst Mitt 56:107–115, 1975.

    CAS  Google Scholar 

  7. Bloom ET, Foley JL, Peterson IA, Geering G, Bernhard M and Trempe G: Anti-tumor activity in human serum: antibodies detecting blood-group.a.like antigen on the surface of tumor cells. Int J Cancer 12:21–31, 1973.

    PubMed  CAS  Google Scholar 

  8. Bluming AZ, Vogel CL, Ziegler JL and Kiryabwire JWM: Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look. J Natl Cancer Inst 48:17–24, 1972.

    PubMed  CAS  Google Scholar 

  9. Boddie AW, Urist MM, Chee DO, Holmes EC and Morton DL: Inhibition of leukocyte migration in agarose by KCl extracts of a human melanoma cell line grown in serum-free medium. Int J Cancer 16:1035–1041, 1975.

    PubMed  Google Scholar 

  10. Bodurtha AJ, Chee DO, Laucius JF, Mastrangelo MJ and Prehn RT: Clinical and immunological significance of human melanoma cytotoxic antibody. Cancer Res 35:189–193, 1975.

    PubMed  CAS  Google Scholar 

  11. Bowen JM, McBride CM, Hersh EM and Miller MF: Nucleolar antigens in tumor cells of patients with malignant melanoma. In: Immunological Aspects of Neoplasia, pp 223–239. Williams & Wilkins, Baltimore, 1975.

    Google Scholar 

  12. Brüggen J, Sorg C and Macher E: Membrane associated antigens of malignant melanoma: V. serological typing of cells using antisera from non-human primates. Cancer Immunol Immunother 5:53–62, 1978.

    Google Scholar 

  13. Burger DR, Vandenbark AA, Finke P, Malley A, Frikke M, Black J, Acott K, Begley D and Vetto RM: Assessment of reactivity to tumor extracts by leukocyte adherence inhibition and dermal testing. J Natl Cancer Inst 59:317–323, 1977.

    Google Scholar 

  14. Bystryn J: Release of cell surface tumor associated antigens by viable melanoma cells from humans. J Natl Cancer Inst 69:325–328, 1977.

    Google Scholar 

  15. Bystryn J and Smalley JR: Identification and solubilization of iodinated cell surface human melanoma associated antigens. Int J Cancer 20:165–172, 1977.

    PubMed  CAS  Google Scholar 

  16. Canevari S, Fossati G and Delia Porta G: Cellular immune reaction to human melanoma and breast carcinoma cells. J Natl Cancer Inst 56:705–709, 1976.

    PubMed  CAS  Google Scholar 

  17. Canevari S, Fossati G, DellaPorta G and Balzarini GP: Humoral cytotoxicity in melanoma patients and its correlation to extent of disease. Int J Cancer 16:722–729, 1975.

    PubMed  CAS  Google Scholar 

  18. Carey TE, Lloyd KO, Takahashi T, Travassos LR and Old LJ: AU cell surface of human malignant melanoma: solubilization and partial characterization. Proc Nat Acad Sci 76:2898–2902, 1979.

    PubMed  CAS  Google Scholar 

  19. Carey TE, Takahashi T, Resnick LA, Oettgen HF and Old LJ: Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Nat Acad Sci 73:3278–3282, 1976.

    PubMed  CAS  Google Scholar 

  20. Carrel S and Theilkaes L: Evidence for a tumor-associated antigen in human malignant melanoma. Nature 242:609–610, 1973.

    PubMed  CAS  Google Scholar 

  21. Char D, Hollingshead A, Cogan DG, Ballintine EJ, Hogan MJ and Herberman RB: Cutaneous delayed hypersensitivity reactions to soluble melanoma antigen in patients with ocular melanoma. N Engl J Med 291:274–277, 1974.

    PubMed  CAS  Google Scholar 

  22. Chee DO, Boddie AW, Roth JA, Holmes EC and Morton DL: Production of melanoma-associated antigens by a defined malignant melanoma cell strain grown in chemically defined medium. Cancer Res 36:1503–1509, 1976.

    PubMed  CAS  Google Scholar 

  23. Cochran AJ, Jehn UW and Gothoskar B: Cell mediated immunity in malignant melanoma. Lancet 1:1340–1341, 1972.

    PubMed  CAS  Google Scholar 

  24. Cochran AJ, Mackie RM, Thomas CE, Grant RM, Cameron-Mowat DE and Spilg WGS: Cellular immunity to breast carcinoma and malignant melanoma. Br J Cancer Suppl 1:77–81, 1973.

    PubMed  CAS  Google Scholar 

  25. Cochran AJ, Ross CE, Mackie RM, Grant RM and Hoyle DE: The immune status of patients with malignant melanoma. Behring Inst Mitt 56:125–130, 1975.

    Google Scholar 

  26. Copeman PWM, Lewis MG, Phillips TM and Elliott PG: Immunological associations of the halo nevus with cutaneous malignant melanoma. Br J Dermatol 88:127, 1973.

    PubMed  CAS  Google Scholar 

  27. Cornain S, DeVries JE, Collard J, Vennegoor C, van Wingerden I and Rumke P: Antibodies and antigen expression in human melanoma detected by the immune adherence test. Int J Cancer 16:981–997, 1975.

    PubMed  CAS  Google Scholar 

  28. Currie GA and Basham C: Serum-mediated inhibition of the immunological reactions of the patient to his own tumor: a possible role for circulating antigen. Br J Cancer 26:427–438, 1972.

    PubMed  CAS  Google Scholar 

  29. Currie GA, Lejeune F and Hamilton-Fairley G: Immunization with irradiated tumor cells and specific lymphocyte cytotoxicity in malignant melanoma. Br Med J 2:305–310, 1971.

    PubMed  CAS  Google Scholar 

  30. Curry RA, Quaranta V, Pellegrino MA and Ferrone S: Serologically detectable human melanoma associated antigens are not genetically linked to HLA-A and HLA-B antigens. J Immunol 122:2630–2632, 1979.

    PubMed  CAS  Google Scholar 

  31. Das Gupta T, Dowden L and Berg TW: Malignant melanoma of unknown primary origin. Surg Gynecol Obstet 117:341–345, 1963.

    Google Scholar 

  32. DeVries JE, Cornain S and Rumke PH: Cytotoxicity of non-T versus T-lymphocytes from melanoma patients and healthy donors on short and long-term cultures melanoma cells. Int J Cancer 14:427–434, 1974.

    CAS  Google Scholar 

  33. DeVries JE, Mendelsohn J and Bont WS: The requirement of monocytes in spontaneous cytotoxicity by lymphocytes from healthy donors and melanoma patients. Int J Cancer 25:73–84, 1980.

    CAS  Google Scholar 

  34. DeVries JE, Cornain S and Rumke PH: Humoral and cellular immunity in melanoma patients. Behring Inst Mitt 56:148–156, 1975.

    Google Scholar 

  35. DeVries JE, Rumke PH and Bernheim JL: Cytotoxic lymphocytes in melanoma patients. Int J Cancer 9:567–576, 1972.

    Google Scholar 

  36. Douwes FR, Spellman HJ, Mross K and Wolfrum DI: Immunodiagnostics of malignant disease: VI. electrophoretic mobility test (EMT) in malignant melanoma. Oncology 35:163–167, 1978.

    PubMed  CAS  Google Scholar 

  37. Eberman AA: Beitrag zur Casuistik der melanotischen Geschwülste. Dtsch Z Chir 11:498, 1896.

    Google Scholar 

  38. Elliott PG, Thurlow B, Needham PRG and Lewis MG: The specificity of the cytoplasmic antigen in human malignant melanoma. Eur J Cancer 9:607–610, 1973.

    PubMed  CAS  Google Scholar 

  39. Embleton MJ and Price MR: Inhibition of in vitro lymphocytotoxic reactions against tumor cells by melanoma membrane extract. Behring Inst Mitt 56:157–160, 1975.

    Google Scholar 

  40. Embleton MJ, Price MR and Baldwin RW: Demonstration and partial purification of common melanoma associated antigens. Eur J Cancer 16:575–585, 1980.

    PubMed  CAS  Google Scholar 

  41. Fabricant RN, DeLarco JE and Todaro GJ: Nerve growth factor receptors on human melanoma cells in culture. Proc Natl Acad Sci 74:565–569, 1977.

    PubMed  CAS  Google Scholar 

  42. Fass L, Ziegler JL, Herberman RB and Kiryabwire JWM: Cutaneous hypersensitivity reactions to autologous extracts of malignant melanoma cells. Lancet 1:116–118, 1970.

    PubMed  CAS  Google Scholar 

  43. Federman JL, Lewis MG and Clark WH: Tumor-associated antibody to ocular and cutaneous melanomas: negative interaction with normal choroidal melanocytes. J Nat Cancer Inst 52:587–589, 1974.

    PubMed  CAS  Google Scholar 

  44. Ferrone S and Pellegrino MA: Cytotoxic antibodies to cultured melanoma cells in the sera of melanoma patients. J Natl Cancer Inst 58:1201–1204, 1978.

    Google Scholar 

  45. Ferrone S and Pellegrino MA: Antigens and antibodies in malignant melanoma. In: Waters H (ed) Handbook of Cancer Immunology, Vol 3, pp 291–327. Garland STPM, New York, 1978.

    Google Scholar 

  46. Fine RN, Batchelor JR, French ME and Shumak KH: The uptake of 125I-labeled rat alloantibody and its loss after combination with antigen. Transplantation 16:641–648, 1973.

    PubMed  CAS  Google Scholar 

  47. Fisher RI, Neifeld JP and Lippman ME: Estrogen receptors in human malignant melanoma. Lancet 1:337–338, 1976.

    Google Scholar 

  48. Fossati G, Colnaghi MI, Delia Porta G, Cascinelli N and Veronesi U: Cellular and humoral immunity against human malignant melanoma. Int J Cancer 8:344–350, 1971.

    PubMed  CAS  Google Scholar 

  49. Fritsche R and Mach JP: Identification of a new oncofetal antigen associated with several types of human carcinomas. Nature 258:734–737, 1975.

    PubMed  CAS  Google Scholar 

  50. Fritze D, Kern DH, Drogemuller CR and Pilch YH: Production of antisera with specificity for malignant melanoma and human fetal skin. Cancer Res 36:458–466, 1976.

    PubMed  CAS  Google Scholar 

  51. Fritze D, Kern DH and Pilch YH: Serologic evidence for cross-reacting tumor associated antigens in two chemically induced murine sarcomas and in human malignant melanoma. Behring Inst Mitt 56:90–97, 1975.

    Google Scholar 

  52. Gauci CL: The macrophage content of human malignant melanomas. Behring Inst Mitt 56:73–78, 1975.

    Google Scholar 

  53. Ghose T, Norvell ST, Guclu A, Bodurtha A, Tai J and MacDonald AS: Immunochemotherapy of malignant melanoma with chlorambucil-bound anti-melanoma globulins: Preliminary results in patients with disseminated disease. J Natl Cancer Inst 58:845–852, 1977.

    PubMed  CAS  Google Scholar 

  54. Ghose T, Norvell ST, Guclu A, Cameron D, Bodurtha A and MacDonald AS: Immunotherapy of cancer with chlorambucil-carrying antibody. Br Med J 3:495–499, 1972.

    PubMed  CAS  Google Scholar 

  55. Golub SH: In vitro sensitization of human lymphoid cells to antigens on cultured melanoma cells. Cell Immunol 28:379–389, 1977.

    PubMed  CAS  Google Scholar 

  56. Goodwin DP, Hornung MO, Leong SPL and Krementz ET: Immune responses induced by human malignant melanoma in the rabbit. Surgery 72:737–743, 1972.

    PubMed  CAS  Google Scholar 

  57. Grimm EA, Silver HKB, Roth JH, Chee DO, Gupta RK and Morton DL: Detection of tumor-associated antigen in human melanoma cell line supernatants. Int J Cancer 17:559–564, 1976.

    PubMed  CAS  Google Scholar 

  58. Gupta RK, Irie RF, Chee DO, Kern DH and Morton DL: Demonstration of two distinct antigens in spent tissue culture medium of a human malignant cell line. J Natl Cancer Inst 63:347–356, 1979a.

    PubMed  CAS  Google Scholar 

  59. Gupta R and Morton DL: Suggestive evidence for in vivo binding of specific antitumor antibodies of human melanoma. Cancer Res 35:58–62, 1975.

    PubMed  CAS  Google Scholar 

  60. Gupta RK, Silver HKB and Morton DL: Production and characterization of xenogeneic antisera to tumor-associated antigen. J Surg Oncol 13:75–89, 1980.

    PubMed  CAS  Google Scholar 

  61. Gupta RK, Theofilopoulos AN, Dixon FJ and Morton DL: Circulating immune complexes as possible cause for anticomplementary activity in humans with malignant melanoma. Cancer Immunol Immunother 6:211–221, 1979b.

    Google Scholar 

  62. Halliday WJ, Maluish AE, Little JH and Davis NC: Leukocyte adherence inhibition and specific immunoreactivity on malignant melanoma. Int J Cancer 16:645–658, 1975.

    PubMed  CAS  Google Scholar 

  63. Hamilton-Fairley G, Lewis MG, Ikonopisov RL, Nairn RC and Alexander P: Detection of tumor specific immune reaction in human melanoma. Ann N Y Acad Sci 177:286–289, 1971.

    Google Scholar 

  64. Handley WS: The pathology of melanocytic growths. Lancet 1:927, 1907.

    Google Scholar 

  65. Hedley DW and Currie GA: Monocytes and macrophages in malignant melanoma: III. reduction of nitroblue tetrazolium by peripheral blood monocytes. Br J Cancer 37:747–752, 1978.

    PubMed  CAS  Google Scholar 

  66. Hellström I, Hellström KE, Sjögren HO and Warner GA: Demonstration of cell-mediated immunity to human neoplasms of various histological types. Int J Cancer 7:1–16, 1971a.

    PubMed  Google Scholar 

  67. Hellström I, Sjögren HO, Warner G and Hellström KE: Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms. Int J Cancer 7:226–237, 1971b.

    PubMed  Google Scholar 

  68. Hellström I, Hellström KE, Sjögren HO and Warner G: Serum factors in tumor-free patients cancelling the blocking of cell-mediated tumor immunity. Int J Cancer 8:185–191, 1971c.

    PubMed  Google Scholar 

  69. Hellström I, Warner GA, Hellström KE and Sjögren HO: Destruction of cultivated melanoma cells by lymphocytes from healthy black (North American Negro) donors. Int J Cancer 11:116–122, 1973a.

    PubMed  Google Scholar 

  70. Hellström I, Warner GA, Hellström KE and Sjögren HO: Sequential studies on cell-mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma. Int J Cancer 11:280–292, 1973b.

    PubMed  Google Scholar 

  71. Hellström I, Hellström KE and Warner GA: Increase of lymphocyte-mediated tumor-cell destruction by certain patient sera. Int J Cancer 12:348–353, 1973c.

    PubMed  Google Scholar 

  72. Heppner G, Stolbach HL, Cummings F, McDonough E and Calabresi P: Cell-mediated and serum blocking reactivity to tumor antigens in patients with malignant melanoma. Int J Cancer 11:245–260, 1973.

    PubMed  CAS  Google Scholar 

  73. Heppner G, Stolbach H, Cummings F, McDonough E and Calabresi P: Problems in the clinical use of the microcytotoxicity assay for measuring cell-mediated immunity to tumor cells. Cancer Res 35:1931–1937, 1975.

    PubMed  CAS  Google Scholar 

  74. Hersey P, Honeyman M, Edwards A, Adams E and McCarthy WH: Antigens on melanoma cells detected by leukocyte dependent antibody assays of human melanoma antisera. Int J Cancer 18:564–573, 1976.

    PubMed  CAS  Google Scholar 

  75. Hersey P, Murray E, Werkmeister J and McCarthy WH: Detection of low molecular weight antigen on melanoma cells by human antiserum in leukocyte dependent antibody assays. Br J Cancer 40:615–627, 1979.

    PubMed  CAS  Google Scholar 

  76. Hersh EM, Gutterman JV, Mavligit GM, Granatek CH, Reed RC, Ambus V and McBride C: Approaches to the study of tumor antigens and tumor immunity in malignant melanoma. Behring Inst Mitt 56:139–147, 1975.

    Google Scholar 

  77. Hollingshead AC: Analysis of soluble melanoma cell membrane antigens in metastatic cells of various organs and further studies of antigens present in primary melanoma. Cancer 36:1282–1288, 1975.

    Google Scholar 

  78. Hollingshead AC, Herberman RB, Jaffurs WJ, Alpers LK, Minton JP and Harris JE: Soluble membrane antigens of human malignant melanoma. Cancer 34:1235–1243, 1974.

    Google Scholar 

  79. Irie K, Irie RF and Morton DL: Detection of antibody and complement complexed in vivo on membranes of human cancer cells by mixed hemadsorption techniques. Cancer Res 35:1244–1248, 1975.

    PubMed  CAS  Google Scholar 

  80. Irie RF, Irie K and Morton DL: Natural antibody in human serum to a neoantigen in human cultured cells grown in fetal bovine serum. J Natl Cancer Inst 52:1051–1058, 1974.

    PubMed  CAS  Google Scholar 

  81. Irie RF, Irie K and Morton DL: A membrane antigen common to cancer and fetal brain tissues. Cancer Res 36:3510–3517, 1976.

    PubMed  CAS  Google Scholar 

  82. Irie RF, Giuliano AE, Morton DL: Oncofetal antigen: a tumor associated fetal antigen immunogenic in man. J Natl Cancer Inst 63:367–373, 1979.

    PubMed  CAS  Google Scholar 

  83. Jacubovich R and Dore JF: Tumor-associated antigens in culture medium of malignant melanoma cell strains. Cancer Immunol Immunother 7:59–64, 1979.

    Google Scholar 

  84. Jehn UW, Nathanson L, Schwartz RS and Skinner M: In vitro lymphocyte stimulation by a soluble antigen from malignant melanoma. N Engl J Med 283:329–333, 1970.

    PubMed  CAS  Google Scholar 

  85. Jerry LM, Rowden G, Cano PO, Phillips TM, Deutsch GF, Capek A, Hartmann D and Lewis MG: Immune complexes in human melanoma. A consequence of deranged immune regulation. Scand J Immunol 5:845–859, 1976.

    PubMed  CAS  Google Scholar 

  86. Kerney SE, Montague PM, Chretien PB, Nicholson JM, Ekel TM and Hearing VJ: Intracellular localization of tumor-associated antigens in murine and human malignant melanoma. Cancer Res 37:1519–1524, 1977.

    PubMed  CAS  Google Scholar 

  87. Kilpatrick RJ and Seigler HF: Specific cytotoxic antibody in sera from patients with melanoma. J Surg Res 21:301–305, 1976.

    PubMed  CAS  Google Scholar 

  88. Kodera Y and Bean MA: Antibody-dependent cell-mediated cytotoxicity for human monolayer target cells bearing blood group and transplantation antigens and for melanoma cells. Int J Cancer 16:579–592, 1975.

    PubMed  CAS  Google Scholar 

  89. Kopf AW, Silberberg I and Cooper NS: Immunohistochemical study of human malignant melanoma for the presence of gamma globulin. J Invest Dermatol 47:83–86, 1966.

    PubMed  CAS  Google Scholar 

  90. Koprowski H, Steplewski Z, Herlyn D and Herlyn M: Study of antibodies against human malignant melanoma produced by somatic cell hybrids. Proc Natl Acad Sci 75:3405–3409, 1978.

    PubMed  CAS  Google Scholar 

  91. Leong SPL, Cooperbrand SR, Sutherland CM, Krementz ET and Deckers PJ: Detection of human melanoma antigens in cell-free supernatants. J Surg Res 24:245–252, 1978.

    PubMed  CAS  Google Scholar 

  92. Leong SPL, Hornung HO and Krementz ET: Immunofluorescent studies on chimpanzee humoral responses to human melanoma cells. Oncology 33:246–249, 1976.

    PubMed  CAS  Google Scholar 

  93. Leong SPL, Sutherland CM and Krementz ET: Immunofluorescent detection of common melanoma membrane antigens by sera of melanoma patients immunized against autologous or allogeneic cultured melanoma cells. Cancer Res 37:4035–4042, 1977a.

    PubMed  CAS  Google Scholar 

  94. Leong SPL, Sutherland CM and Krementz ET: Changes in distribution of human malignant melanoma membrane antigens in the presence of human antibody by immunofluorescence. Cancer Res 37:293–298, 1977b.

    PubMed  CAS  Google Scholar 

  95. Lewis MG, Avis PJG, Phillips TM and Sheikh KMA: Tumor-associated antigens in human malignant melanoma. Yale J Biol Med 46:661–668, 1973.

    PubMed  CAS  Google Scholar 

  96. Lewis MG: Possible immunological factors in human malignant melanoma in Uganda. Lancet 2:921–922, 1967.

    PubMed  CAS  Google Scholar 

  97. Lewis MG, Ikonopisov RL, Nairn RC, Phillips TM, Hamilton-Fairley G, Bodenham DC and Alexander P: Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of disease. Br Med J 3:547–552, 1969.

    PubMed  CAS  Google Scholar 

  98. Lewis MG and Phillips TM: Separation of two distinct tumor-associated antibodies in the serum of melanoma patients. J Natl Cancer Inst 49:915–917, 1972a.

    PubMed  CAS  Google Scholar 

  99. Lewis MG and Phillips TM: The specificity of surface membrane immunofluorescence in human malignant melanoma. Int J Cancer 10:105–111, 1972b.

    PubMed  CAS  Google Scholar 

  100. Lewis MG, Phillips TM, Cook KB and Blake J: Possible explanations for loss of detectable antibodies in patients with disseminated malignant melanoma. Nature 232:52–54, 1971.

    PubMed  CAS  Google Scholar 

  101. Lewis MG and Raymond MJ: Humoral and cellular host reactions to melanoma antigens. Behring Inst Mitt 56:120–125, 1975.

    Google Scholar 

  102. Liao S, Leong SPL, Sutherland CM, Dent PB, Kwong PC and Krementz ET: Common human melanoma membrane antigens detected by mixed hemadsorption microassay with serum from a patient undergoing immunotherapy with autologous tumor cells. Cancer Res 38:4395–4400, 1978.

    PubMed  CAS  Google Scholar 

  103. Liao S, Kwong PC, Thompson JC and Dent PB: Spectrum of melanoma antigens on cultured human malignant melanoma cells as detected by monkey antibodies. Cancer Res 39:183–192, 1979.

    PubMed  CAS  Google Scholar 

  104. Lieberman R, Wybran J and Epstein W: The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma. Cancer 35:756–777, 1975.

    PubMed  CAS  Google Scholar 

  105. Macher E, Muller CHR, Sorg G, Gossen A and Sorg C: Evidence for cross-reacting membrane associated specific melanoma antigens as detected by immunofluorescence and immune adherence. Behring Inst Mitt 56:86–90, 1975.

    Google Scholar 

  106. Mackie RM, Spilg WGS, Thomas CE and Cochran AJ: Cell-mediated immunity in patients with malignant melanoma. Br J Dermatol 87:523–528, 1972.

    PubMed  CAS  Google Scholar 

  107. Malley A, Burger DR, Vandenbark AA, Frikke P, Begley D, Acott K, Black J and Vetto RM: Association of melanoma tumor antigen with B2-microglobulin. Cancer Res 39:619–623, 1979.

    PubMed  CAS  Google Scholar 

  108. Marti JH and Thomson DPM: Anti-tumor immunity in malignant melanoma assayed by tube leukocyte adherence inhibition. Br J Cancer 34:116–133, 1976.

    PubMed  CAS  Google Scholar 

  109. Martin EW, Kibbey WE, DeVecchia L, Anderson G, Catalano P and Minton JP: Carcinoembryonic antigen: clinical and historical aspects. Cancer 37:62–81, 1976.

    PubMed  Google Scholar 

  110. Mazuran R, Mujagic H, Malenica B and Silobrcic V: In vitro detection of cellular immunity to melanoma antigens in man by the monocyte spreading inhibition test. Int J Cancer 17:14–20, 1976.

    PubMed  CAS  Google Scholar 

  111. Mastrangelo MJ, Bellet RE and Berd D: Immunology and immunotherapy of human cutaneous malignant melanoma. In: Clark WH, Goldman LI and Mastrangelo MJ (eds) Human Malignant Melanoma, pp 355–416. Grune & Stratton, New York, 1979.

    Google Scholar 

  112. McCabe RP, Ferrone S, Pellegrino MA, Kern DH, Holmes EC and Reisfeld RA: Purification and immunologic evaluation of human melanoma-associated antigens. J Natl Cancer Inst 60:773–777, 1979.

    Google Scholar 

  113. McCabe RP, Indiveri F, Galloway DR, Ferone S and Reisfeld RA: Lack of association of serologically detectable human melanoma-associated antigens with B2-microglobulin : serologic and immunologic evidence. J Natl Cancer Inst 65:707–707, 1980.

    Google Scholar 

  114. McCabe RP, Quaranta V, Frugis L, Ferrone S and Reisfeld RA: A radioimmunometric antibody binding assay for evaluation of xenoantisera to melanoma associated antigens. J Natl Cancer Inst, 1979.

    Google Scholar 

  115. McCarty KS, Jr, Wortman J, Stowers S, Lubahn DB, McCarty KS, Sr and Seigler HF: Sex steroid receptor analysis in human melanoma. Cancer 46:1463–1470, 1980.

    PubMed  Google Scholar 

  116. McCoy JL, Jerome LF, Dean JH, Perlin E, Oldham RK, Char DH, Cohen MH, Felix EL and Herberman RB: Inhibition of leukocyte migration by tumor associated antigens in soluble extracts of human melanoma. J Natl Cancer Inst 55:19–23, 1975.

    PubMed  CAS  Google Scholar 

  117. Metzgar RS, Bergoc PM, Moreno MA and Seigler HF: Melanoma specific antibodies produced in monkeys by immunization with human melanoma cell lines. J Natl Cancer Inst 50:1065–1068, 1973.

    PubMed  CAS  Google Scholar 

  118. Mihalev A, Tzingilev D and Sirakov LM: Radioimmunoassay of alphafetoprotein in the serum of patients with leukemia and malignant melanoma. Neoplasma 23:103–107, 1976.

    PubMed  CAS  Google Scholar 

  119. Minden P, Jarrett C, McClatchy JK, Gutterman JU and Hersh EM: Antibodies to melanoma cell and BCG antigens in sera from tumor-free individuals and from melanoma patients. Nature 263:774–777, 1976b.

    PubMed  CAS  Google Scholar 

  120. Minden P, Sharpton TR and McClatchy JK: Shared antigens between human malignant melanoma cells and mycobacterium bovis (BCG). J Immunol 116:1407–1414, 1976a.

    PubMed  CAS  Google Scholar 

  121. Morgan G, McCarthy WH, Hersey P: Detection of carcinoembryonic-like antigen on melanoma cells by leukocyte-dependent antibody assays. Br J Cancer 36:446–452, 1977.

    PubMed  CAS  Google Scholar 

  122. Morton DL, Eilber FR, Malmgren RA and Wood WC: Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68:158–164, 1970.

    PubMed  CAS  Google Scholar 

  123. Morton DL, Malmgren RA, Holmes EC and Ketcham AS: Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 64:233–240, 1968.

    PubMed  CAS  Google Scholar 

  124. Mukherji B, Vassos D, Flowers A, Binder SC and Nathanson L: Selective and non-selective lymphocytotoxicity in human melanoma: observation on the effect of long-term culture and fetal bovine serum on target cell sensitivity to lymphocytes. Int J Cancer 16:971–980, 1975.

    PubMed  CAS  Google Scholar 

  125. Muna N, Marcus S and Smart C: Detection by immunofluorescence of antibodies specific for human malignant melanoma cells. Cancer 34:1712–1721, 1969.

    Google Scholar 

  126. Murray E, Ruygrok S, Milton GW and Hersey P: Analysis of serum blocking factors against leukocyte-dependent antibody in melanoma patients. Int J Cancer 21:578–587, 1978.

    PubMed  CAS  Google Scholar 

  127. Mutzner PA, Stuhlmiller GM and Seigler HF: Characterization of melanoma cell membrane tumor associated antigens using xenoserum, alloserum and autoserum: I. immunofluorescence. J Surg Oncol 14:367–377, 1980.

    PubMed  CAS  Google Scholar 

  128. Myburgh JA and Smit JA: Prolongation of liver allograft survival by donor-specific soluble transplantation antigens and antigen-antibody complexes. Transplantation 19:64–71, 1975.

    PubMed  CAS  Google Scholar 

  129. Nagel GA, Piessens WF, Stilmont MM and Lejeune F: Evidence for tumor-specific immunity in human malignant melanoma. Eur J. Cancer 7:41–47, 1971.

    PubMed  CAS  Google Scholar 

  130. Nairm RC, Nind APP, Guli BPG, Davies DJ, Little JH, Davis NC and Whitehead RH: Anti-tumour immunity in patients with malignant melanoma. Med J Aust 1:397–403, 1972.

    Google Scholar 

  131. Nimmberg RB, Glasgow AH, Memzoian JO, Constantian MB, Cooperband SR, Mannick JA and Schmid K: Isolation of an immunosuppressive peptide fraction from the serum of cancer patients. Cancer Res 35:1489–1494, 1975.

    Google Scholar 

  132. Nind APP, Nairn RC, Rolland JM, Guli EPG and Hughes ESR: Lymphocyte anergy in patients with carcinoma. Br J Cancer 28:108–117, 1973.

    PubMed  CAS  Google Scholar 

  133. Ninnemann JB: Melanoma-associated immunosuppression through B-cell activation of suppressor T-cells. J Immunol 120:1573–1579, 1978.

    PubMed  CAS  Google Scholar 

  134. Nishioka K, Romsdahl MM, Fritsche HA and McMertrey MH: Tyrosinase activity in the sera of patients with malignant melanoma: method and specificity. Int J Cancer 20:289–293, 1977.

    Google Scholar 

  135. Nishioka K, Romsdahl MM and McMertrey MH: Comparative studies of tyrosinases of malignant melanoma and correlation to serum tyrosinase in patients with malignant melanoma. Cancer Biochem Biophys 2:145–150, 1978.

    CAS  Google Scholar 

  136. Oettgen HF, Aoki T, Old LJ, Boyse EA, DeHarven E and Mills GM: Suspension culture of a pigment-producing cell line derived from a human malignant melanoma. J Natl Cancer Inst 41:827–831, 1969.

    Google Scholar 

  137. Parks L, Smith W and Williams G: Distinction of allogeneic immunity from tumor-specific immunity in man. Surgery 76:43–49, 1974.

    PubMed  CAS  Google Scholar 

  138. Parsons PG, Goss P and Pope JH: Detection in human melanoma cell lines of particles with some properties in common with RNA tumor viruses. Int J Cancer 13:606–618, 1974.

    PubMed  CAS  Google Scholar 

  139. Parsons PG, Klucis E, Goss PD, Pope JH, Little JH and Davis NC: Oncornavirus-like particles in malignant melanoma. Int J Cancer 18:757–763, 1976.

    PubMed  CAS  Google Scholar 

  140. Pavie-Fischer J, Kourilsky FM, Banzet P, Puissant A and Levy JP: Investigation of cell-mediated immune reactions in malignant melanoma using the chromium release test. Behring Inst Mitt 56:160–167, 1975.

    Google Scholar 

  141. Peter HH, Diehl V, Kalden JR, Seeland P and Eckert G: Humoral and cellular cytotoxicity in vitro against allogeneic human melanoma cells. Behring Inst Mitt 56:167–177, 1975a.

    Google Scholar 

  142. Peter HH, Pavie-Fischer J, Fridman WH, Aubert C, Cesarin J, Roubin R and Kourilsky FM: Cell-mediated cytotoxicity in vitro of human lymphocytes against a tissue culture melanoma cell line (IGR3). J Immunol 115:539–548, 1975b.

    PubMed  CAS  Google Scholar 

  143. Powell AE, Sloss AM, Smith RN, Makley JT and Hubay CA: Specific responsiveness of leukocytes to soluble extracts of human tumors. Int J Cancer 16:905–913, 1975.

    PubMed  CAS  Google Scholar 

  144. Preddie E, Hartmann D and Lewis MG: Human melanoma tumor specific antigens. (1) an allogeneic antigen from patient “PY” melanoma tumor cell plasma membranes. Cancer Biochem Biophys 2:161–167, 1978.

    CAS  Google Scholar 

  145. Preddie E, Hartmann D, Persad S, Khosravi M, and Lewis M: Isolation of an autologous tumor-specific antigen from tumor cell plasma membranes of a human melanoma patient. Cancer Biochem Biophys 2:199–202, 1978.

    CAS  Google Scholar 

  146. Prehn RT and Main JM: Immunity to methyl-cholanthrene-induced sarcomas. J Natl Cancer Inst 18:769–778, 1957.

    PubMed  CAS  Google Scholar 

  147. Rahman AFR, Liao SK and Dent PB: Characterization of human malignant melanoma cell lines. In Vitro 13:580–583, 1977.

    PubMed  CAS  Google Scholar 

  148. Reid T and Albert DM: RNA-dependent DNA polymerase activity in human tumors. Biochem Biophys Res Commun 46:383–390, 1972.

    PubMed  CAS  Google Scholar 

  149. Reisfeld RA, David GS, Ferrone S, Pellegrino MA and Holmes EC: Approaches for the isolation of biologically functional tumor-associated antigens. Cancer Res 37:2860–2865, 1977.

    PubMed  CAS  Google Scholar 

  150. Roenigk HH, Jr, Deodhar SD and Krebs JA: Microcytotoxicity and serum blocking factors in malignant melanoma and halo nevus. Arch Dermatol III:720–725, 1975.

    Google Scholar 

  151. Romsdahl SA and Cox IS: Human malignant melanoma antibodies demonstrated by immunofluorescence. Arch Surg Chicago 100:491–497, 1970.

    PubMed  CAS  Google Scholar 

  152. Roth JA, Holmes EC, Reisfeld RA, Slocum HK and Morton DL: Isolation of a soluble tumor associated antigen from human melanoma. Cancer 37:104–110, 1976.

    PubMed  CAS  Google Scholar 

  153. Roth JA, Slocum HK, Pellegrino MA, Holmes EC and Reisfeld RA: Purification of soluble human melanoma-associated antigens. Cancer Res 36:2360–2364, 1976.

    PubMed  CAS  Google Scholar 

  154. Salinas FA, Sheikh KM and Chandor SB: Serological reactivity in cancer patients to human and mouse fetal liver cells. Cancer Res 38:401–407, 1978.

    PubMed  CAS  Google Scholar 

  155. Sample WF, Gertner HR and Chretien PB: Inhibition of phytohemagglutinin-induced in vitro lymphocyte transformation by serum from patients with carcinoma. J Natl Cancer Inst 46:1291–1297, 1971.

    PubMed  CAS  Google Scholar 

  156. Seigler HF, Shingleton WW, Metzgar RS, Buckley CE and Bergoc PM: Immunotherapy in patients with melanoma. Ann Surg 178:352–359, 1973.

    Google Scholar 

  157. Shepherd PS: A comparison of two 125I Clq binding tests to detect soluble immune complexes in serum of patients with malignant disease. Clin Exp Immunol 36:250–255, 1979.

    PubMed  CAS  Google Scholar 

  158. Sherwin SA, Sliski AH and Todaro GJ: Human melanoma cells have both nerve growth factor and nerve growth factor receptors on their cell surfaces. Proc Natl Acad Sci 76:1288–1292, 1979.

    PubMed  CAS  Google Scholar 

  159. Shiku H, Takahashi T, Oettgen HF and Old LJ: Cell surface antigens of human malignant melanoma: II. serologic typing with immune adherence assays and definition of two new surface antigens. J Exp Med 144:873–881, 1976.

    PubMed  CAS  Google Scholar 

  160. Shiku H, Takahashi T, Resnick LA, Oettgen HF and Old LJ: Cell surface antigens of human malignant melanoma: III. recognition of autoantibodies with unusual characteristics. J Exp Med 145:784–789, 1977.

    PubMed  CAS  Google Scholar 

  161. Sidell N, Irie RF and Morton DL: Oncofetal antigen I: a target for immune cytolysis of human cancer. Br J Cancer 40:950–953, 1979.

    PubMed  CAS  Google Scholar 

  162. Siebert E, Sorg C, Happle R and Macher E: Membrane associated antigens of human malignant melanoma: III. specificity of human sera reacting with cultured melanoma cells. Int J Cancer 19:172–178, 1977.

    Google Scholar 

  163. Sjögren HO, Hellström I, Bansal SC and Hellström KE: Suggestive evidence that “blocking anibodies” of tumor-bearing individuals may be antigen-antibody complexes. Proc Natl Acad Sci 68:1372–1375, 1971.

    PubMed  Google Scholar 

  164. Smith JL and Stehlin JS: Spontaneous regression of primary malignant melanoma with regional metastases. Cancer 18:1399–1415, 1965.

    PubMed  Google Scholar 

  165. Smithers DW: Spontaneous regression of cancer. Ann R Coll Surg Engl 41:160–162, 1967.

    PubMed  CAS  Google Scholar 

  166. Snyderman R, Seigler HF and Meadows L: Abnormalities of monocyte chemotaxis in patients with melanoma: effects of immunotherapy and tumor removal. J Natl Cancer Inst 58:37–41, 1977.

    PubMed  CAS  Google Scholar 

  167. Steplewski Z, Herlyn M, Herlyn D, Clark WH and Koprowski H: Reactivity of monoclonal anti-melanoma antibodies with melanoma cells freshly isolated from primary and metastatic melanoma. Eur J Immunol 9:94–96, 1979.

    PubMed  CAS  Google Scholar 

  168. Stewart THM: The presence of delayed hypersensitivity reactions in patients toward extracts of their malignant tumors: I. the role of tissue antigen, non-specific reactions of nuclear material and bacterial antigen as a cause for this phenomenon. Cancer 23:1368–1379, 1969.

    PubMed  CAS  Google Scholar 

  169. Stuhlmiller GM, Boylston JA, Seigler HF and Fetter BF: Immunodiagnosis of melanoma using chimpanzee antihuman melanoma antiserum. Am J Clin Pathol 67:573–579, 1977.

    PubMed  CAS  Google Scholar 

  170. Stuhlmiller GM, Green RW and Seigler HF: Solubilization and partial isolation of human melanoma tumor associated antigens. J Natl Cancer Inst 61:61–67, 1978.

    PubMed  CAS  Google Scholar 

  171. Stuhlmiller GM and Seigler HF: Immunology and Immunotherapy of Melanoma. In: Waters H (ed) Handbook of Cancer Immunology, Vol 5, pp 315–343. Garland STPM, New York, 1978.

    Google Scholar 

  172. Stuhlmiller GM and Seigler HF: Enzymatic susceptibility and spontaneous release of human melanoma tumor associated antigens. J Natl Cancer Inst 58:215–221, 1977.

    PubMed  CAS  Google Scholar 

  173. Stuhlmiller GM and Seigler HF: Characterization of a chimpanzee antihuman melanoma antiserum. Cancer Res 35:2132–2137, 1975.

    PubMed  CAS  Google Scholar 

  174. Sumner WC and Foraker AG: Spontaneous regression of human melanoma: clinical and experimental studies. Cancer 13:79–81, 1960.

    PubMed  CAS  Google Scholar 

  175. Takasugi M, Mickey M and Terasaki PI: Reactivity of lymphocytes from normal persons on cultured tumor cells. Cancer Res. 33:2898–2901, 1973.

    PubMed  CAS  Google Scholar 

  176. Takasugi M, Mickey M and Terasaki PI: Studies on the specificity of cell-mediated immunity to human tumors. J Natl Cancer Inst 53:1527–1538, 1974.

    PubMed  CAS  Google Scholar 

  177. The TH, Huiges NA, Schraffordt-Koops H, Lamberts HB and Niewg HO: Surface antigens on cultured malignant melanoma cells as detected by a membrane immunofluorescence method with human sera. Lack of tumor-specific reactions on melanoma lines. Ann N Y Acad Sci 254:528–540, 1975.

    PubMed  CAS  Google Scholar 

  178. Thomson DMP, Gold P, Freedman SO and Shuster J: The isolation and characterization of tumor-specific antigens of rodent and human tumors. Cancer Res 36:3518–3525, 1976.

    PubMed  CAS  Google Scholar 

  179. Thomson DMP, Rauch JE, Weatherhead JC, Friedlander P, O’Conner R, Grossner N, Shuster J and Gold P: Isolation of tumor-specific antigens associated with B2-microglobulin. Br J Cancer 37:753–775, 1978.

    PubMed  CAS  Google Scholar 

  180. Thomson DMP, Tataryn DN, Schwartz R and MacFarlane JK: Abrogation of the phenomenon of leukocyte adherence inhibition by excess circulating tumour antigen. Eur J Cancer 15:1095–1106, 1979.

    PubMed  CAS  Google Scholar 

  181. Theofilopoulus AN, Andrews BS, Vrist MM, Morton DL and Dixon FJ: The nature of immune complexes in human cancer sera. J Immunol 119:657–663, 1977.

    Google Scholar 

  182. Thorpe WP, Parker GA and Rosenberg SA: Expression of fetal antigen by normal human skin cells grown in tissue culture. J Immunol 119:818–823, 1977.

    PubMed  CAS  Google Scholar 

  183. Todd DW, Spencer-Payne W, Farrow GM and Winklemann RK: Spontaneous regression of primary malignant melanoma with regional metastases: report of a case of photographic documentation. Proc Mayo Clin 41:10–17, 1966.

    Google Scholar 

  184. Tomecki KJ, Montague PM and Hearing VJ: Serum and urine protein differences in patients with malignant melanoma. J Natl Cancer Inst 64:29–32, 1980.

    PubMed  CAS  Google Scholar 

  185. Vanderbark AA, Greene MH, Burger DR, Vetto RM and Reimer RR: Immune response to melanoma extracts in three melanoma-prone families. J Natl Cancer Inst 63:1147–1151, 1979.

    Google Scholar 

  186. Viza D and Phillips J: Extraction and solubilization of cell surface antigens from malignant melanomas. Rev Inst Pasteur Lyon 4:339–342, 1971.

    Google Scholar 

  187. Viza D and Phillips J: Identification of an antigen associated with malignant melanoma. Int J Cancer 16:312–317, 1975.

    PubMed  CAS  Google Scholar 

  188. Viza D, Phillips J and Bourgoin JJ: Detection of specific antigens in the serum of melanoma patients. Rev Inst Pasteur Lyon 6:321–324, 1973.

    Google Scholar 

  189. Weese JL, Herberman RB, Hollingshead AC, Cannon GB, Keels M, Kibrite A, Morales A, Char DH and Oldham RK: Specificity of delayed cutaneous hypersensitivity responses to extracts of human tumor cells. J Natl Cancer Inst 60:255–263, 1978.

    PubMed  CAS  Google Scholar 

  190. Whitehead RH: Fluorescent antibody studies in malignant melanoma. Br J Cancer 28:525–529, 1973.

    PubMed  CAS  Google Scholar 

  191. Wilson BS, Indiveri F, Pellegrino MA and Ferrone S: Dr (Ia-like) antigens on human melanoma cells. J Exp Med 149:658–668, 1979.

    PubMed  CAS  Google Scholar 

  192. Winchester RJ, Wang C, Gibofsky A, Kunkel HG, Lloyd KO and Old LJ: Expression of la-like antigens on cultured human malignant melanoma cell lines. Proc Natl Acad Sci 75:6235–6239, 1978.

    PubMed  CAS  Google Scholar 

  193. Wood GW and Barth RF: Immunofluorescent studies of the serologic reactivity of patients with malignant melanoma against tumor-associated cytoplasmic antigens. J Natl Cancer Inst 53:309–316, 1974.

    PubMed  CAS  Google Scholar 

  194. Wood GW and Gollahon KA: Detection and quantitation of macrophage infiltration into primary human tumors with the use of cell surface markers. J Natl Cancer Inst 59:1081–1087, 1977.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Gary M. Stuhlmiller
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Duke University Medical Center, Durham, North Carolina, USA

    H. F. Seigler

Rights and permissions

Reprints and permissions

Copyright information

© 1982 Martinus Nijhoff Publishers, The Hague/Boston/London

About this chapter

Cite this chapter

Stuhlmiller, G.M. (1982). Immunobiology of melanoma. In: Seigler, H.F. (eds) Clinical Management of Melanoma. Developments in Oncology, vol 5. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-7493-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-7493-7_8

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-009-7495-1

  • Online ISBN: 978-94-009-7493-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation